An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury

NCT01814982 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped reprioritization of company activities

Conditions

Traumatic Brain Injury

Interventions

DRUG: JNJ-17299425

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.